CO5080733A1 - Metodos y composiciones para estimular el crecimiento de neuritas - Google Patents
Metodos y composiciones para estimular el crecimiento de neuritasInfo
- Publication number
- CO5080733A1 CO5080733A1 CO97066753A CO97066753A CO5080733A1 CO 5080733 A1 CO5080733 A1 CO 5080733A1 CO 97066753 A CO97066753 A CO 97066753A CO 97066753 A CO97066753 A CO 97066753A CO 5080733 A1 CO5080733 A1 CO 5080733A1
- Authority
- CO
- Colombia
- Prior art keywords
- straight
- branched
- alkyl
- alkenyl
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un composición aceptable farmacéuticamente comprende;a).- Una cantidad neurotrófica de un compuesto que contiene la fórmula (I)<EMI FILE="97066753_1" ID="1" IMF=JPEG >y derivados farmacéuticamente aceptables de este, en donde:A es CH2, oxígeno, o NR1;En donde R1, B y D son independientemente: hidrógeno, Ar, alquilo (C1-C6) recto o ramificado, alquenilo o alquinilo (C2-C6 ) recto o ramificado, alquilo (C1-C6 ) recto o ramificado sustituido con cicloalquilo (C5-C7), alquenilo o alquinilo recto o ramificado (C3-C6) sustituido con cicloalquilo (C5-C7), alquilo recto o ramificado (C1-C6) sustituido con cicloalquenilo (C5-C7), alquenilo o alquinilo recto o ramificado (C3-C6 ) sustituido con cicloalquenilo (C5-C7), alquilo recto o ramificado (C1-C6) sustituido con Ar, o alquenilo o alquinilo recto o ramificado (C3-C6 ) sustituido con Ar;En donde cualquiera de los grupos CH2 de dicha cadena de alquilo en R1, B y D son reemplazados opcionalmente por 0, S, SO, SO2 , o Nr;En donde R es hidrógeno, alquilo recto o ramificado (C-C4) , alquenilo o alquinilo o ramificado (C3-C4), o alquilo punteado (C1-C4) en donde el puente es formado entre el nitrógeno y el átomo de carbono de dicha cadena alquilo para formar un anillo, y donde dicho anillo es opcionalmente fusionado con Ar;J es seleccionado a partir de hidrógeno, alquilo recto o ramificado (C1-C6 ) alquenilo recto o ramificado con (C3-C6), o -CH2 Ar;K se selecciona a partir de alquilo recto o ramificado (C1-C4), -CH2 Ar, o ciclohexilmetilo; oJ y K se toman juntos con átomos de nitrógeno o carbono a los cuales ellos se ligan respectivamente para formar un anillo heterocíclico con 5 a7 miembros que opcionalmente contienen un heteroátomo seleccionado a partir de 0, S, SO, SO2 ; Z es 0 ó S; - 2 -Y es O o N, en donde, cuando Y es 0, entonces R1 es un par único y R2 se selecciona a partir de Ar, alquilo recto o ramificado (C1-C6), o alquenilo recto o ramificado (C3-C6); y cuando Y es N, entonces R1 y R2 son independientemente seleccionados del grupo que consiste de Ar, alquilo recto o ramificado (C1-C6), o alquenilo o alquinilo recto o ramificado con (C3-C6); o R1 y R2 se toman juntos para formar un anillo heterocíclico con 5 a 6 miembros seleccionado de pirrolidina, imidazolidina, pirazolidina, piperidina, o piperazina;en donde Ar es un grupo aromático carboxílico seleccionado a partir del grupo que consiste de fenilo, 1-naftilo, 2-naftilo, indenilo, azulenilo, fluorenilo o antracenilo, 2-furilo, 3-furilo, 2-tienilo, 3-tienilo, 2-piridilo, 3-piridilo, 4-piridilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, 2-pirazolinilo, pirazolidinilo, isoxazolilo, isotriazolilo, 1,2,3-oxadiazolilo, 1, 2,3-triazolilo, 1,3,4-tiadiazolilo, piridazinilo, pirimidinilo, pirazinilo, 1,3,5-triazinilo, 1,3,5-tritianilo, indolizinilo, isoindolilo, 3H-indolilo, indolinilo, benzo [b] furanilo, benzo [b] tiofenilo, 1H-indazolilo, benzimidazolilo, benzitiazolilo, purinilo, 4H-quinolizinilo, quinolinilo, 1,2,3,4-tetrahidro-isoquinolinilo, isoquinolinilo, 1,2,3,4-tetrahidro-isoquinolinilo, cinnolinilo, eftalazinilo, quinazolinilo, quinoxalinilo, 1,8-naftiridinilo, pteridinilo, carbazolilo, acridinilo, fenazinilo, fenotiazinilo o fenoxazinilo; en donde Ar es opcionalmente sustituido con uno o tres sustituyentes independientemente seleccionados de hidrógeno, halógeno, hidroxilo, nitro, SO3H, trifluorometilo, trifluorometoxi, alquilo recto o ramificado (C1-C6), alquenilo recto o ramificado (C2-C6), o-[alquilo recto o ramificado (C1-C6)], o -[alquenilo recto o ramificado (C3-C4)], o-benzilo, o-fenilo, 1,2-metilenedioxi, -R3 R4, carboxilo, N-(alquilo recto o ramificado (C1-C5) o alquenilo recto o ramificado (C3-C5) carboxamidas, N,N-di-(alquilo recto o ramificado (C1-C5)o alquenilo recto o ramificado (C3-C5) carboxamida, morfolinilo, piperidinilo, O-Z, CH2-(CH2)q -Z, 0-(CH2)q -Z, (CH2 )q -Z-O-Z, o CH=CH-Z; en donde R3 y R4 son seleccionados independientemente a partir de alquilo recto o ramificado (C1-C6)alquenilo recto o ramificado (C3-C6) hidrógeno o benzilo; o en donde R3 y R4 son tomados juntos para formar un anillo heterocíclico con 5 a 6 miembros; en donde Z se selecciona a partir de 4-metoxifenilo, 2-piridilo, 3-piridilo, 4-piridilo, pirazilo, quinolilo, 3,5-dimetilisoxazoilo, 2-metiltioazoilo, tiazoilo, 2-tienilo, 3-tienilo, 4-tienilo o pirimidilo; en donde q es 0-2; y n es 0 o 1; b) un factor neurotrófico; y c) un portador adecuado farmacéuticamente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/749,114 US5780484A (en) | 1996-11-13 | 1996-11-13 | Methods for stimulating neurite growth with piperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5080733A1 true CO5080733A1 (es) | 2001-09-25 |
Family
ID=25012320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97066753A CO5080733A1 (es) | 1996-11-13 | 1997-11-13 | Metodos y composiciones para estimular el crecimiento de neuritas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5780484A (es) |
| EP (2) | EP1666053A1 (es) |
| JP (1) | JP2001503778A (es) |
| KR (1) | KR100537866B1 (es) |
| CN (1) | CN1168443C (es) |
| AR (1) | AR015105A1 (es) |
| AU (1) | AU741186B2 (es) |
| BR (1) | BR9713037A (es) |
| CA (1) | CA2270985A1 (es) |
| CO (1) | CO5080733A1 (es) |
| EA (1) | EA003530B1 (es) |
| IL (1) | IL129557A0 (es) |
| IN (1) | IN183409B (es) |
| NZ (1) | NZ335396A (es) |
| PL (1) | PL191249B1 (es) |
| TW (1) | TW509572B (es) |
| UA (1) | UA61090C2 (es) |
| WO (1) | WO1998020893A1 (es) |
| ZA (1) | ZA9710248B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150527A (en) * | 1994-08-18 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Synthetic multimerizing agents |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US6133456A (en) * | 1994-08-18 | 2000-10-17 | Ariad Gene Therapeutics, Inc. | Synthetic multimerizing agents |
| US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| ZA98825B (en) * | 1997-02-27 | 1998-10-19 | Guilford Pharm Inc | Method of using neurotrophic carbamates and ureas |
| US6242468B1 (en) | 1997-02-27 | 2001-06-05 | Jia-He Li | Carbamate and urea compositions and neurotrophic uses |
| US6514686B2 (en) | 1997-04-28 | 2003-02-04 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| US5945441A (en) | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
| US6852496B1 (en) | 1997-08-12 | 2005-02-08 | Oregon Health And Science University | Methods of screening for agents that promote nerve cell growth |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| WO1999062880A1 (en) | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
| IL140039A0 (en) * | 1998-06-03 | 2002-02-10 | Guilford Pharm Inc | Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| KR20010071920A (ko) | 1998-07-17 | 2001-07-31 | 개리 이. 프라이드만 | 뉴우런 성장 및 연장을 자극하는 화합물, 조성물 및 방법 |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| US6395758B1 (en) | 1998-08-14 | 2002-05-28 | Gpi Nil Holdings, Inc. | Small molecule carbamates or ureas for vision and memory disorders |
| US6376517B1 (en) * | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
| US7338976B1 (en) * | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
| US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
| US6228872B1 (en) * | 1998-11-12 | 2001-05-08 | Bristol-Myers Squibb Company | Neurotrophic diamide and carbamate agents |
| WO2001002368A1 (en) | 1999-07-06 | 2001-01-11 | Vertex Pharmaceuticals Incorporated | N-heterocyclic derivatives with neuronal activity |
| US6734211B1 (en) | 1999-07-09 | 2004-05-11 | Oregon Health & Sciences University | Compositions and methods for promoting nerve regeneration |
| HUP0202249A3 (en) * | 1999-07-09 | 2003-01-28 | Ortho Mcneil Pharm Inc | Neurotrophic pyrrolidines and piperidines, compositions containing them and use of the compounds |
| MXPA02002578A (es) | 1999-09-08 | 2002-10-23 | Guilford Pharm Inc | Compuestos de union a ciclofilina no peptidicos, y su uso. |
| ES2269206T3 (es) * | 1999-11-12 | 2007-04-01 | Alcon, Inc. | Ligandos de neurofilina para tratar trastornos oculares. |
| US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
| US6417189B1 (en) | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
| US6818643B1 (en) | 1999-12-08 | 2004-11-16 | Bristol-Myers Squibb Company | Neurotrophic bicyclic diamides |
| ATE319712T1 (de) | 1999-12-21 | 2006-03-15 | Mgi Gp Inc | Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung |
| CA2435829A1 (en) | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| EP1404325A2 (en) * | 2001-05-29 | 2004-04-07 | Guilford Pharmaceuticals Inc. | Method for treating nerve injury caused by surgery |
| US20040147433A1 (en) * | 2001-06-14 | 2004-07-29 | Marcus Keep | Neuroimmunophilins for selective neuronal radioprotection |
| WO2003062773A1 (en) * | 2002-01-24 | 2003-07-31 | Pei Electronics, Inc. | Compact integrated infrared scene projector |
| EP1546103B1 (en) * | 2002-10-03 | 2009-03-18 | Vertex Pharmaceuticals Incorporated | Piperazine and piperidine derivatives for treatment of neurological diseases |
| US20060189551A1 (en) * | 2004-10-04 | 2006-08-24 | Duke University | Combination therapies for fungal pathogens |
| ATE549342T1 (de) * | 2004-12-20 | 2012-03-15 | Wyeth Llc | Rapamycinanaloge und deren verwendungen bei der behandlung proliferativer, entzündlicher und neurologischer störungen |
| EP1828203A2 (en) | 2004-12-20 | 2007-09-05 | Wyeth | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders |
| MX2007010076A (es) | 2005-02-17 | 2007-10-16 | Astellas Pharma Inc | Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo. |
| JP2009525319A (ja) * | 2006-02-02 | 2009-07-09 | ライナット ニューロサイエンス コーポレイション | ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法 |
| AU2007210862A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744485A (en) * | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
| US5543423A (en) * | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
| IL115685A (en) * | 1994-11-16 | 2000-08-31 | Vertex Pharma | Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof |
| US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US6037370A (en) * | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| WO2014051091A1 (ja) * | 2012-09-28 | 2014-04-03 | Dic株式会社 | α－アルミナ微粒子及びその製造方法 |
-
1996
- 1996-11-13 US US08/749,114 patent/US5780484A/en not_active Expired - Lifetime
-
1997
- 1997-11-13 ZA ZA9710248A patent/ZA9710248B/xx unknown
- 1997-11-13 IL IL12955797A patent/IL129557A0/xx not_active IP Right Cessation
- 1997-11-13 CA CA002270985A patent/CA2270985A1/en not_active Abandoned
- 1997-11-13 EA EA199900463A patent/EA003530B1/ru not_active IP Right Cessation
- 1997-11-13 IN IN2147CA1997 patent/IN183409B/en unknown
- 1997-11-13 PL PL333286A patent/PL191249B1/pl not_active IP Right Cessation
- 1997-11-13 JP JP52286798A patent/JP2001503778A/ja active Pending
- 1997-11-13 NZ NZ335396A patent/NZ335396A/xx unknown
- 1997-11-13 EP EP06000328A patent/EP1666053A1/en not_active Ceased
- 1997-11-13 AU AU54397/98A patent/AU741186B2/en not_active Ceased
- 1997-11-13 CO CO97066753A patent/CO5080733A1/es unknown
- 1997-11-13 BR BR9713037-0A patent/BR9713037A/pt not_active Application Discontinuation
- 1997-11-13 KR KR10-1999-7004194A patent/KR100537866B1/ko not_active IP Right Cessation
- 1997-11-13 EP EP97948309A patent/EP0941113A1/en not_active Ceased
- 1997-11-13 UA UA99063269A patent/UA61090C2/uk unknown
- 1997-11-13 WO PCT/US1997/020868 patent/WO1998020893A1/en not_active Application Discontinuation
- 1997-11-13 AR ARP970105320A patent/AR015105A1/es not_active Application Discontinuation
- 1997-11-13 CN CNB971802483A patent/CN1168443C/zh not_active Expired - Fee Related
- 1997-11-13 TW TW086116912A patent/TW509572B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EA003530B1 (ru) | 2003-06-26 |
| ZA9710248B (en) | 1998-05-28 |
| AU741186B2 (en) | 2001-11-22 |
| UA61090C2 (uk) | 2003-11-17 |
| AR015105A1 (es) | 2001-04-18 |
| CA2270985A1 (en) | 1998-05-22 |
| WO1998020893A1 (en) | 1998-05-22 |
| CN1168443C (zh) | 2004-09-29 |
| NZ335396A (en) | 2000-11-24 |
| EP1666053A1 (en) | 2006-06-07 |
| IL129557A0 (en) | 2000-02-29 |
| EA199900463A1 (ru) | 2000-02-28 |
| AU5439798A (en) | 1998-06-03 |
| BR9713037A (pt) | 2000-04-11 |
| IN183409B (es) | 1999-12-25 |
| US5780484A (en) | 1998-07-14 |
| PL333286A1 (en) | 1999-11-22 |
| KR20000068964A (ko) | 2000-11-25 |
| PL191249B1 (pl) | 2006-04-28 |
| CN1239434A (zh) | 1999-12-22 |
| TW509572B (en) | 2002-11-11 |
| JP2001503778A (ja) | 2001-03-21 |
| KR100537866B1 (ko) | 2005-12-21 |
| EP0941113A1 (en) | 1999-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5080733A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO4930260A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO4920219A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO5080734A1 (es) | Compuestos amino que poseen actividad neuronal | |
| CO5640104A2 (es) | Derivados de aminoisoxazol activos como inhibidores de quinasa | |
| CO5261503A1 (es) | Derivados de piperazina y piperidina | |
| YU22402A (sh) | Nova klasa agenasa za citodiferencijaciju i inhibitora histon deacetilaze, i postupci za njihovu upotrebu | |
| HUP0400694A2 (hu) | A rotamáz enzim aktivitásának kis molekulájú inhibitorai, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
| AR035205A1 (es) | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas | |
| ES2112332T3 (es) | Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico. | |
| AR015765A1 (es) | Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento. | |
| ES2174579T3 (es) | Nuevos derivados benzotiofenicos, benzofuranicos e indolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| NO984740L (no) | Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler | |
| JP2001514177A5 (es) | ||
| ES2007543A6 (es) | Procedimiento de preparacion de 1,4-dihidropiridinas. | |
| US5225420A (en) | Use of tetrahydrothienopyridine derivatives as angiogenesis inhibitors | |
| NO930499L (no) | Benzimidazolderivater, fremgangsmaate for deres fremstilling og deres anvendelse | |
| FI964436A (fi) | Uudet hydroksiimijohdannaiset, niitä sisältävät farmaseuttiset koostumukset sekä menetelmä niiden valmistamiseksi | |
| DK0429370T3 (da) | Hiditl ukendte thiophenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem | |
| AR002259A1 (es) | Derivados de 1-oxo-2-(fenilsulfonilamino)pentilpiperidina, su preparacion, compuestos intermedios y composicion que contiene a dichos derivados. | |
| DK290086D0 (da) | I 17-stillingen substituerede sparteinderivater og deres anvendelse som laegemidler | |
| IL133448A0 (en) | Benzo (5, 6) cyclohepta (1, 2-b) pyridine derivatives as farnesyl protein transferase inhibitors | |
| AR035660A1 (es) | Compuestos 3,10-dibromo-8-cloro-11h-benzo[5,6]ciclohepta[1,2-b]piridin-11-il-4-piperidinilos o sus sales farmaceuticamente aceptables, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un procedimiento para producir un compuesto intermediario para produ | |
| ATE380028T1 (de) | Mittel zur anregung des appetits und mittel zur behandlung von anorexie | |
| RU97120755A (ru) | Соединения тетралина с активностью по отношению к устойчивости ко многим лекарственным препаратам |